3’-Deoxy-3’-[ 18 F]Fluorothymidine—[ 18 F]FLT is a Positron Emission Tomography (PET) tracer which has been used for noninvasive assessment of proliferation activity in several types of cancer. During the past few years, some novel approaches for [ 18 F]FLT synthesis have been developed, mainly focused on optimization of reaction conditions and purification methods. The present study reports the use of two different eluents in the final step of [ 18 F]FLT production and the evaluation of its effect on radiochemical yield and product quality. The first eluent evaluated was water: ethanol (90:10, v/v), commercially available, and the second was NaCl 0.9% (saline): ethanol (92:8, v/v). The mean of the corrected radiochemical yields corresponded to 27% ± 7% for elution with water and ethanol and to 23% ± 3% for elution with saline and ethanol, which could indicate that the eluent solutions have similar elution strength. Besides, quality control results were in accordance with the requirements and demonstrated that there was no significant difference between both formulations. Considering that pharmaceutical preparations containing ethanol should be preferentially diluted with saline to avoid hemolysis, the eluent saline:ethanol (92:8, v/v) was chosen for [ 18 F]FLT extraction and final formulation.
Coleman, R. (1998) Clinical PET in Oncology. Clinical Positron Imaging, 1, 15-30. https://doi.org/10.1016/S1095-0397(97)00004-6
Kostakoglu, L., Agress, H. and Goldsmith, S.J. (2003) Clinical Role of FDG PET in Evaluation of Cancer Patients. Radiographics, 23, 315-340. https://doi.org/10.1148/rg.232025705
Kumar, R., Dhanpathi, H., Basu, S., Rubello, D., Fanti, S. and Alavi, A. (2008) Oncologic PET Tracers beyond [ 18 F]FDG and the Novel Quantitative Approaches in PET Imaging. The Quarterly Journal of Nuclear Medicine and Molecular Imaging, 52, 50-65. http://www.minervamedica.it/en/getfreepdf/9DBCUdDjVvU2fITHy83h5ooFLgNjXpdgNfXDCNnG% 252F4QgSaTKs79V9qre7Ob0K6z%252BNBAtuepQ0Sf6DSzD4MiWow%253D%253D/R39Y 2008N01A0050.pdf
Rohren, E.M., Turkington, T.G. and Coleman, R.E. (2004) Clinical Applications of PET in Oncology. Radiology, 231, 305-332. https://doi.org/10.1148/radiol.2312021185
Lee, Y. (2010) Radiopharmaceuticals for Molecular Imaging. The Open Nuclear Medicine Journal, 2, 178-185. https://doi.org/10.2174/1876388X01002010178 http://benthamopen.com/contents/pdf/TONMEDJ/TONMEDJ-2-178.pdf
Grierson, J.R. and Shields, A.F. (2000) Radiosynthesis of 3’-Deoxy-3'-[(18)F] Fluorothymidine: [(18)F]FLT for Imaging of Cellular Proliferation in Vivo. Nuclear Medicine and Biology, 27, 143-156. https://doi.org/10.1016/S0969-8051(99)00104-3
Been, L.B., Suurmeijer, A.J., Cobben, D.C., Jager, P.L., Hoekstra, H.J. and Elsinga, P.H. (2004) [ 18 F]FLT-PET in Oncology: Current Status and Opportunities. European Journal of Nuclear Medicine and Molecular Imaging, 31, 1659-1672. https://doi.org/10.1007/s00259-004-1687-6
Groves, A.M., Win T., Haim, S.B. and Ell, P.J. (2007) Non-[ 18 F]FDG PET in Clinical Oncology. The Lancet Oncology, 8, 822-830. https://doi.org/10.1016/S1470-2045(07)70274-7
Bertagna, F., Biasiotto, G. and Giubbini, R. (2013) The Role of F-18-Fluorothymidine PET in Oncology. Clinical and Translational Imaging, 1, 77-97. https://doi.org/10.1007/s40336-013-0014-2
Fuchs, K., et al. (2013) In Vivo Imaging of Cell Proliferation Enables the Detection of the Extent of Experimental Rheumatoid Arthritis by 3’-Deoxy-3’- 18 F-Fluorothymidine and Small-Animal PET. Journal of Nuclear Medicine, 54, 151-158. https://doi.org/10.2967/jnumed.112.106740
Langen, P., Etzold, Z., Hintsche, R. and Kowollik, G. (1969) 3’Deoxy-3’Fluorothymidine, a New Selective Inhibitor of DNA Synthesis. Acta Biologica et Medica GERMANICA, 23, 759-766.
Kong, X.B., et al. (1992) Comparisons of Anti-Human Immunodeficiency Virus Activities, Cellular Transport, and Plasma and Intracellular Pharmacokinetics of 3'-Fluoro-3'-Deoxy-thymidine and 3'-Azido-3'-Deoxythymidine. Antimicrobial Agents and Chemotherapy, 36, 808-818. https://doi.org/10.1128/AAC.36.4.808
Ghosn, J., et al. (2007) Antiviral Activity of Low Dose Alovudine in Antiretroviral-Experienced Patients: Results from a 4-Week Randomized, Double-Binded, Placebo-Controlled Dose-Ranging Trial. HIV Medicine, 8, 142-147. https://doi.org/10.1111/j.1468-1293.2007.00444.x
Bading, J.R. and Shields, A.F. (2008) Imaging of Cell Proliferation: Status and Prospects. Journal of Nuclear Medicine, 49, 64S-80S. https://doi.org/10.2967/jnumed.107.046391
Wilson, I.K., Chatterjee, S. and Wolf, W. (1991) Synthesis of 3’-Fluoro-3’-Deoxythymidine and Studies of Its 18 F-Radiolabeling, as a Tracer for the Non-Invasive Monitoring of the Biodistribution of Drugs against AIDS. Journal of Fluorine Chemistry, 55, 283-289. https://doi.org/10.1016/S0022-1139(00)82356-8
Shields, A.F., Grierson, J.R., Kozawa, S.M. and Zheng M. (1996) Development of Labeled Thymidine Analogs for Imaging Tumor Proliferation. Nuclear Medicine and Biology, 23, 17-22. https://doi.org/10.1016/0969-8051(95)02005-5
Grierson J.R. and Shields, A.F. (1997) Development of a Radiosynthesis for 3’-[ 18 F]Fluoro-3’-Deoxy-Nucleosides. Journal of Labelled Compounds and Radiopharmaceuticals, 40, 60-62.
Grierson, J.R. and Shields, A.F. (1999) An Improved Synthesis of [ 18 F]FLT. Journal of Labelled Compounds and Radiopharmaceuticals, 42, S525-S526.
Tang, G., Tang, X., Wena, F., Wangc, M. and Lic, B. (2010) A Facile and Rapid Automated Synthesis of 3’-Deoxy-3’-[ 18 F]Fluorothymidine. Applied Radiation and Isotopes, 68, 1734-1739. https://doi.org/10.1016/j.apradiso.2010.04.010
Pascali, C., et al. (2012) Simple Preparation and Purification of Ethanol-Free Solutions of 3’-Deoxy-3’-[ 18 F]Fluorothymidine by Means of Disposable Solid-Phase Extraction Cartridges. Nuclear Medicine and Biology, 39, 540-550. https://doi.org/10.1016/j.nucmedbio.2011.10.005
Niedermoser, S., et al. (2012) Evaluation of an Automated Double-Synthesis Module: Efficiency and Reliability of Subsequent Radiosyntheses of FHBG and FLT. Nuclear Medicine and Biology, 39, 586-592. https://doi.org/10.1016/j.nucmedbio.2011.10.018
Oh, S.J., et al. (2004) Fully Automated Synthesis System of 3’-Deoxy-3’-[ 18 F]Fluorothymidine. Nuclear Medicine and Biology, 31, 803-809. https://doi.org/10.1016/j.nucmedbio.2004.01.008
ICH (2013) The International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. www.ich.org
Strickley, R.G. (2004) Solubilizing Excipients in Oral and Injectable Formulations. Pharmaceutical Research, 21, 201-230. https://doi.org/10.1023/B:PHAM.0000016235.32639.23
Scott, P.J.H. and Hockley, B.G. (2012) Radiochemical Syntheses, Volume 1: Radiopharmaceuticals for Positron Emission Tomography. John Wiley and Sons, Hoboken.
Serdons, K., Verbruggen, A. and Bormans, G. (2008) The Presence of Ethanol in Radiopharmaceutical Injections. Journal of Nuclear Medicine, 49, 2071. https://doi.org/10.2967/jnumed.108.057026
Kuntzsch, M., Lamparter, D., Brüggener, N., Müller, M., Kienzle, G.J. and Reischl, G. (2014) Development and Successful Validation of Simple and Fast TLC Spot Tests for Determination of Kryptofix® 2.2.2 and Tetrabutylammonium in 18 F-Labeled Radiopharmaceuticals. Pharmaceuticals, 7, 621-633. https://doi.org/10.3390/ph7050621
Yun, M., Oh, S.J., Ha, H.J., Ryu, J.S. and Moon, D.H. (2003) High Radiochemical Yield Synthesis of 3’-Deoxy-3’-[ 18 F]Fluorothymidine Using (5-O-Dimethoxytrityl-2’-Deoxy-3’-O-Nosyl-D-Threopentofuranosyl)Thymine and Its 3-N-BOC-Protected Analogue as a Labeling Precursor. Nuclear Medicine and Biology, 30, 151-157. https://doi.org/10.1016/S0969-8051(02)00409-2
Grierson, J.R. and Shields, A. (2000) Radiosynthesis of 3’-Deoxy-3’-[ 18 F]Fluorothymidine: [ 18 F]FLT for Imaging of Cellular Proliferation in Vivo. Nuclear Medicine & Biology, 27, 143-156. https://doi.org/10.1016/S0969-8051(99)00104-3
European Pharmacopoeia 8.0 (2014) Council of Europe, Strasbourg.
USP (2015) United States Pharmacopeial Convention. 38th Edition, Rockville.
The International Pharmacopoeia (2015). 5th Edition. http://apps.who.int/phint/en/p/docf/
Paproski, R.J., Ng, A.M., Yao, S.Y., Graham, K., Young, J.D. and Cass, C.E. (2008) The Role of Human Nucleoside Transporters in Uptake of 3’-Deoxy-3’-Fluorothymidine. Molecular Pharmacology, 74, 1372-1380. https://doi.org/10.1124/mol.108.048900
Brockenbrough, J.S., et al. (2011) Tumor 3’-Deoxy-3’- 18 F-Fluorothymidine ( 18 F-FLT) Uptake by PET Correlates with Thymidine Kinase 1 Expression: Static and Kinetic Analysis of 18 F-FLT PET Studies in Lung Tumors. Journal of Nuclear Medicine, 52, 1181-1188. https://doi.org/10.2967/jnumed.111.089482
Viertl, D., et al. (2011) Increase of [ 18 F]FLT Tumor Uptake In Vivo Mediated by FdUrd: Toward Improving Cell Proliferation Positron Emission Tomography. Molecular Imaging and Biology, 13, 321-331. https://doi.org/10.1007/s11307-010-0368-z